Whitehawk Therapeutics signs option deal for up to five new ADC programs May 21, 2026 05:05PM
Whitehawk Therapeutics (WHWK) Reiterated at Market Outperform by Citizens After Q1 Results May 11, 2026 04:15AM
Whitehawk Therapeutics, Inc. (WHWK) Misses Q1 EPS by 29c May 7, 2026 08:06AM
Citizens Starts Whitehawk Therapeutics (WHWK) at Market Outperform Apr 16, 2026 03:35AM
Whitehawk presents data on MUC16 target for gynecologic cancer treatment Apr 10, 2026 07:01AM


Mar 12, 2026 08:35AM Whitehawk Therapeutics, Inc. (WHWK) Tops Q4 EPS by 35c
Feb 5, 2026 09:30AM Oppenheimer Starts Whitehawk Therapeutics (WHWK) at Outperform
Jan 8, 2026 08:05AM Whitehawk receives FDA clearance for cancer drug trial, submits second application
Dec 22, 2025 12:08PM Jones Trading Starts Whitehawk Therapeutics (WHWK) at Buy
Nov 20, 2025 04:00AM Jefferies Reiterates Hold Rating on Whitehawk Therapeutics (WHWK)
Nov 6, 2025 04:14PM Whitehawk Therapeutics, Inc. (WHWK) Tops Q3 EPS by 22c
Oct 24, 2025 12:31PM Whitehawk Therapeutics presents data on PTK7 as cancer drug target
Oct 16, 2025 08:32AM Tempus partners with Whitehawk Therapeutics for cancer research
Aug 7, 2025 09:34AM Whitehawk Therapeutics, Inc. (WHWK) Misses Q2 EPS by 101c
May 8, 2025 07:39PM Whitehawk Therapeutics, Inc. (WHWK) Tops Q1 EPS by 218c
Mar 26, 2025 08:01AM Whitehawk Therapeutics (WHWK) Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals